Dr. Grünwald on Dovitinib Versus Sorafenib in mRCC
September 30th 2013Viktor Grünwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.
Read More